the use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia

Treatment for acute lymphoblastic leukemia (all) in adults confers a high risk of venous thromboembolic (vte) complications. we describe the implementation and results of prophylactic anticoagulation guidelines in adults (18–50 years) treated on a dana-farber cancer institute all pediatric inspired consortium protocol from 2007 to 2013. a high rate of asparaginase related toxicity events, including thrombosis, resulted in a protocol amendment adding guidelines for prophylactic anticoagulation and a modified asparaginase dose and schedule. after excluding patients with philadelphia positive all, a cohort of 36 patients were treated after the protocol amendment with prophylactic anticoagulation and compared to 49 patients who received no prophylactic anticoagulation. bleeding complications were not significantly different in those treated with prophylactic anticoagulation compared with those enrolled prior to the amendment (p = 0.26). no patients on prophylactic anticoagulation had grade ≥ 3 bleeding. prior to the amendment, the 2 year cumulative incidence of vte post-induction was 41% compared to 28% while on prophylactic anticoagulation (p = 0.32). the 2 year cumulative incidence pulmonary embolus pre-amendment was 16% compared with 8% post-amendment (p = 0.34). prophylactic anticoagulation can be safely administered to adults with all without increasing the number or severity of bleeding events and, in addition to modifications in the asparaginase regimen, resulted in a reduction in the cumulative incidence of vte.